ChengXin

Chengdu Chengxin Pharmaceutical is a clinical-stage biotechnology company based in Chengdu, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. The company's research focuses on the DNA damage response (DDR) and protein degradation pathways to address unmet needs in cancer treatment. Its lead candidate, CX-3002, is a highly selective inhibitor of Ubiquitin Specific Peptidase 1 (USP1), which has demonstrated significant potential in treating tumors with BRCA mutations or homologous recombination deficiency (HRD). CX-3002 is currently undergoing Phase 1 clinical trials in both China and the United States. Chengxin Pharmaceutical continues to expand its pipeline with several pre-clinical programs targeting novel mechanisms in cancer biology. The company aims to provide next-generation targeted therapies that can overcome resistance to existing treatments like PARP inhibitors.